Taking into account possible challenges due to China's corruption crackdown
14/09/23 -"Despite Q1 exceeding expectations, thanks to healthy top-line growth and margin improvements, our target price resets c.10% lower due to potential headwinds related to the Chinese clampdown on ..."
Pages
61
Language
English
Published on
14/09/23
You may also be interested by these reports :
10/02/26
Philips’ Q4 results exceeded expectations, with comparable sales growth driven by strong performance in Personal Health and healthy contributions ...
06/02/26
Coloplast delivered a weak Q1, with both revenue and adjusted EBIT missing consensus. Organic growth of 6% was in line with expectations, but ...
06/02/26
Qiagen’s Q4 results surpassed both market expectations and management’s guidance, with most segments reporting gains. The 2026 guidance aligns with ...
05/02/26
GN’s Q4 results fell short of market expectations. While Hearing experienced healthy growth, this was overshadowed by weaknesses in Gaming and ...